Advances in targeted therapy for osteosarcoma based on molecular classification
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in targeted therapy for osteosarcoma based on molecular classification
Authors
Keywords
Osteosarcoma, Molecular classification, Targeted therapy, Personalized medicine
Journal
PHARMACOLOGICAL RESEARCH
Volume -, Issue -, Pages 105684
Publisher
Elsevier BV
Online
2021-05-19
DOI
10.1016/j.phrs.2021.105684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
- (2021) Gianni Chessari et al. JOURNAL OF MEDICINAL CHEMISTRY
- An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
- (2021) Hiromichi Oshiro et al. Scientific Reports
- Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
- (2020) Takashi Ando et al. Cancers
- Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway
- (2020) Xin Wu et al. Cancer Cell International
- Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
- (2019) Kathryn E. Yost et al. Scientific Reports
- Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma
- (2019) Zhenjiang Zhao et al. MOLECULAR CARCINOGENESIS
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model
- (2019) TAKASHI HIGUCHI et al. ANTICANCER RESEARCH
- Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations
- (2019) Yoshiyuki Suehara et al. CLINICAL CANCER RESEARCH
- Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma
- (2019) Gian Luca Negri et al. JOURNAL OF PATHOLOGY
- Derivation of Rapamycin: Adventures in Natural Product Chemistry
- (2019) Sylvain Cottens et al. CHIMIA
- ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
- (2019) Zulekha A. Qadeer et al. CANCER CELL
- Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
- (2019) Christopher L. Heidler et al. INTERNATIONAL JOURNAL OF CANCER
- Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
- (2018) Yubing Zhou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients
- (2018) Julien Masliah-Planchon et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Osteosarcoma, Chondrosarcoma, and Chordoma
- (2018) Jeremy S. Whelan et al. JOURNAL OF CLINICAL ONCOLOGY
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
- (2018) Giovanni Grignani et al. LANCET ONCOLOGY
- c-Myc is a major determinant for antitumor activity of Aurora A kinase inhibitor MLN8237 in thyroid cancer
- (2018) Yiqi Li et al. THYROID
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
- (2017) D. Matthew Gianferante et al. Nature Reviews Endocrinology
- Pazopanib for second recurrence of osteosarcoma in pediatric patients
- (2017) Katsutsugu Umeda et al. PEDIATRICS INTERNATIONAL
- Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
- (2017) Sam Behjati et al. Nature Communications
- Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
- (2016) M. Bousquet et al. ANNALS OF ONCOLOGY
- The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα
- (2016) M Ying et al. ONCOGENE
- A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma
- (2016) Peter M. Anderson et al. PEDIATRIC BLOOD & CANCER
- Stalled replication forks within heterochromatin require ATRX for protection
- (2016) M S Huh et al. Cell Death & Disease
- Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells
- (2016) Jir-You Wang et al. Stem Cells Translational Medicine
- Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling
- (2015) Wan Daqian et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma
- (2015) Rui Yang et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
- (2015) RYOSUKE HORIE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
- (2015) Michal Kovac et al. Nature Communications
- Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
- (2015) Jennifer L. Anderson et al. PLoS One
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†
- (2014) J. S. Whelan et al. ANNALS OF ONCOLOGY
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance
- (2014) Alberto S. Pappo et al. CANCER
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
- (2014) Emmy D.G. Fleuren et al. INTERNATIONAL JOURNAL OF CANCER
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
- (2014) Jennifer A. Perry et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling
- (2013) Claudia Fumarola et al. BREAST CANCER RESEARCH AND TREATMENT
- Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
- (2013) E Tavanti et al. BRITISH JOURNAL OF CANCER
- MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
- (2013) C. Tovar et al. CANCER RESEARCH
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
- (2013) Brenda Weigel et al. PEDIATRIC BLOOD & CANCER
- Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
- (2013) Rochelle Bagatell et al. PEDIATRIC BLOOD & CANCER
- MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
- (2012) B. Wang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE
- (2012) J. Thariat et al. ANNALS OF ONCOLOGY
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
- (2012) Irène Asmane et al. EUROPEAN JOURNAL OF CANCER
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
- (2012) A N Rettew et al. Oncogenesis
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
- (2011) Hans Gelderblom et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma
- (2011) Yin-He Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program
- (2011) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program
- (2011) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
- (2009) R. T. Kurmasheva et al. CANCER RESEARCH
- Prognostic factors and outcomes for osteosarcoma: An international collaboration
- (2009) Emilios E. Pakos et al. EUROPEAN JOURNAL OF CANCER
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
- (2009) Lisa Mirabello et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
- (2009) Ymera Pignochino et al. Molecular Cancer
- Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
- (2008) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now